首页> 美国卫生研究院文献>Biochemical Journal >Inhibition of the specific binding of human lactotransferrin to human peripheral-blood phytohaemagglutinin-stimulated lymphocytes by fluorescein labelling and location of the binding site.
【2h】

Inhibition of the specific binding of human lactotransferrin to human peripheral-blood phytohaemagglutinin-stimulated lymphocytes by fluorescein labelling and location of the binding site.

机译:通过荧光素标记和结合部位的定位来抑制人乳铁传递蛋白与人外周血植物血凝素刺激的淋巴细胞的特异性结合。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Labelling of human lactotransferrin with fluorescein 5'-isothiocyanate (FITC) in an equimolar ratio inhibits the binding of the protein to phytohaemagglutinin-activated human peripheral-blood lymphocytes. Therefore it can be assumed that FITC reacts at, or near, the receptor-binding site. Three FITC-labelled peptides have been purified from a tryptic digest of the FITC-labelled lactotransferrin. The determination of their amino acid sequence and their localization on the primary structure of the protein permitted the identification of two FITC-accessible areas in the N-terminal lobe and one in the C-terminal lobe. In fact, only 10% of the total FITC was conjugated to one lysine residue (Lys579) of the C-terminal lobe, whereas most (80%) of the FITC was conjugated to three close lysine residues [Lys263 (65% of total fluorescence), Lys280 and Lys282 (15% of total fluorescence)] located in beta-turn structures, of the N-terminal domain I of human lactotransferrin. The results obtained show that the receptor-binding site should be located in the vicinity of the FITC-accessible Lys263, Lys280 and Lys282, and corroborate our preliminary results reporting the involvement of the N-terminal domain I in the binding of human lactotransferrin to mitogen-stimulated lymphocytes [Rochard, Legrand, Mazurier, Montreuil & Spik (1989) FEBS Lett. 255, 201-204]. In any case, FITC labelling is not suitable for studying the binding of lactotransferrin to activated lymphocytes and its use may lead to erroneous interpretations of cell binding experiments.
机译:用等摩尔比的荧光素5'-异硫氰酸酯(FITC)标记人乳铁传递蛋白可抑制蛋白质与植物血凝素激活的人外周血淋巴细胞的结合。因此,可以假定FITC在受体结合位点处或附近反应。已从FITC标记的乳铁传递蛋白的胰蛋白酶消化物中纯化了三种FITC标记的肽。确定它们的氨基酸序列并确定其在蛋白质一级结构上的位置,可以鉴定出N端叶中两个FITC可及区域和C端叶中的一个。实际上,总FITC的只有10%与C端叶的一个赖氨酸残基(Lys579)结合,而FITC的大部分(80%)与三个紧密的赖氨酸残基[Lys263(总荧光的65% ),Lys280和Lys282(占总荧光的15%)]位于人乳铁传递蛋白N末端结构域I的β-turn结构中。获得的结果表明,受体结合位点应位于FITC可访问的Lys263,Lys280和Lys282附近,并证实了我们的初步结果,即报告了N末端结构域I参与人乳铁传递蛋白与促细胞分裂剂的结合刺激的淋巴细胞[Rochard,Legrand,Mazurier,Montreuil&Spik(1989)FEBS Lett。 255,201-204]。在任何情况下,FITC标记都不适合研究乳运铁蛋白与活化淋巴细胞的结合,其使用可能导致细胞结合实验的错误解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号